AKT Combination Increased PFS in Metastatic HR-Positive/HER2-Negative Breast Cancer

(MedPage Today) — CHICAGO — Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with the AKT inhibitor ipatasertib added to fulvestrant after first-line CDK4/6 inhibition, a randomized…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115871

Author :

Publish date : 2025-06-03 15:20:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

AKT Combination Increased PFS in Metastatic HR-Positive/HER2-Negative Breast Cancer

Do Pregnant Women Need COVID Boosters?

Parenting Training Reduces Healthcare Needs for Kids With Asthma Plus ADHD

Related Posts

HPV and Skin Cancer; Polygenic Risk Score for Obesity; Rare Flu Complication in Kids

War Is a Global Health Catastrophe

An Ohio Couple Welcomes a Baby Boy From a Nearly 31-Year-Old Frozen Embryo

Brisk Walking May Help You Live Longer

Major Medical Groups Pushed Out of Role Supporting CDC’s Vaccine Advisors

‘It’s Gonna Be (Ly)me’: Justin Timberlake Brings Attention, Awareness to Disease

HPV and Skin Cancer; Polygenic Risk Score for Obesity; Rare Flu Complication in Kids

War Is a Global Health Catastrophe

An Ohio Couple Welcomes a Baby Boy From a Nearly 31-Year-Old Frozen Embryo

Brisk Walking May Help You Live Longer

Major Medical Groups Pushed Out of Role Supporting CDC’s Vaccine Advisors

‘It’s Gonna Be (Ly)me’: Justin Timberlake Brings Attention, Awareness to Disease

ACOG No Longer Accepting Federal Funding, Citing Policy Disputes

States Sue Trump, Say Targeting of Hospitals Over Gender Care in Minors Is Unlawful

Categories

Archives